Limitations of direct-to-consumer advertising for clinical genetic testing

JAMA

Volumn 288, Issue 14, 2002, Pages 1762-1767

  Gollust, Sarah E ^a   Hull, Sara Chandros ^a   Wilfond, Benjamin S ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; ARTICLE; CONSUMER; DRUG INDUSTRY; EDUCATION; ETHNIC GROUP; FEAR; FOOD AND DRUG ADMINISTRATION; GENERAL ASPECTS OF DISEASE; GENETICS; HUMAN; INFORMATION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SOCIAL ENVIRONMENT;

EID: 0037048668     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.14.1762     Document Type: Article

References (70)

1. Lee T, Brennan T. Direct-to-consumer marketing of high technology screening tests. N Engl J Med. 2002;346:529-531.
2. Rosenthal M, Berndt E, Donohue J, Frank R, Epstein A. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346:498-505.
3. Wolfe S. Direct-to-consumer advertising: education or emotion promotion? N Engl J Med. 2002;346:524-526.
4. Hollon MF. Direct-to-consumer marketing of prescription drugs. JAMA. 1999;281:382-384.
5. Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA. 1999;281:380-382.
6. Holtzman NA, Watson MS, eds. Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing. Baltimore, Md: Johns Hopkins University Press; 1998.
7. McConnell LM, Koenig BA, Greely HT, Raffin TA. Genetic testing and Alzheimer disease: recommendations of the Stanford Program in Genomics, Ethics, and Society. Genet Test. 1999;3:3-12.
8. Enhancing the oversight of genetic tests: recommendations of the SACGT. Secretary's Advisory Committee on Genetic Testing, July 2000. Available at: http: //www4.od.nih.gov/oba/sacgt/gtdocuments.html. Accessed June 10, 2002.
9. New Jersey Jewish News. July 25, 2001:S5.
10. The Gazette (Damascus, Md, edition). January 23, 2002:A-8.
11. Fit Pregnancy. August/September 2001:39.
12. Coping. September/October 2001:31.
13. Hadassah Magazine. November 2001:25.
14. Hull SC, Prasad K. Reading between the lines: direct-to-consumer advertising of genetic testing. Hastings Cent Rep. 2001;31:33-35.
15. Frost & Sullivan. US Genetic Testing Markets. San Jose, Calif: Market Engineering Report Service; October 2001.
16. Graham J. Gene-test makers woo consumers. Chicago Tribune. September 8, 2002; sect 1:12.
17. Huang AJ. The rise of direct-to-consumer advertising of prescription drugs in the United States. JAMA. 2000;284:2240.
18. Integrated share of voice and competitive media reporting. US leading products by DTC spend. Fairfield, Conn: IMS Health. Available at: http://www .imshealth.com/public/structure/dispcontent /1,2779,1203-1203-143221,00.html. Accessed November 19, 2001.
19. Scott-Levin's Promotional Audits and Source Prescription Audit, Spring 2001. Newtown, Pa: Scott-Levin; 2001.
20. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med. 1999;14:651-657.
21. Slaughter E. Fifth Annual Survey: Consumer Reactions to Direct-to-Consumer Advertising. Emmaus, Pa: Prevention Magazine; 2002.
22. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Drug Marketing Advertising and Communications. Attitudes and behaviors associated with direct-to-consumer (DTC) promotion of prescription drugs: main survey results. Available at: http://www.fda.gov/cder/ddmac /dtcindex.htm. Accessed November 4, 2001.
23. Statement of Nancy M. Ostrove, Deputy Director, Division of Drug Marketing, Advertising and Communications, FDA. Hearing on Direct-to-Consumer Advertising (DTC). Subcommittee on Consumer Affairs, Foreign Commerce, and Tourism. US Senate Committee on Commerce, Science, and Transportation. July 24, 2001.
24. Statement of John E. Calfee, American Enterprise Institute. Hearing on Direct-to-Consumer Advertising (DTC). Subcommittee on Consumer Affairs, Foreign Commerce, and Tourism. US Senate Committee on Commerce, Science, and Transportation. July 24, 2001.
25. Kravitz RL. Direct-to-consumer advertising of prescription drugs: implications for the patient-physician relationship. JAMA. 2000;284:2244.
26. Tanne JH. Direct to consumer drug advertising is billion dollar business in US. BMJ. 1999;319:805.
27. Berger JT, Kark P, Rosner F, Packer S, Bennett AJ. Direct-to-consumer drug marketing: public service or disservice? Mt Sinai J Med. 2001;68:197-202.
28. Bell RA, Wilkes MS, Kravitz RL. The educational value of consumer-targeted prescription drug print advertising. J Fam Pract. 2000;49:1092-1098.
29. Carson P. The battle over full-body scans. Manag Care. 2001;10:43-46.
30. Sugarman J, Kaalund V, Kodish E, et al, for the Working Group on Ethical Issues in Umbilical Cord Blood Banking. Ethical issues in umbilical cord blood banking. JAMA. 1997;278:938-943.
31. Talamo J. LASIK advertising 2000: are we putting our wallets in front of our wisdom? J Refract Surg. 2000;16:689.
32. Eddy D. Probabilistic reasoning in clinical medicine. In: Kahneman D, Slovic P, Tversky A, eds. Judgement Under Uncertainty: Heuristics and Biases. Cambridge, England: Cambridge University Press; 1982: 249-267.
33. Hoffrage U, Lindsey S, Hertwig R, Gigerenzer G. Medicine: communicating statistical information. Science. 2000;290:2261-2262.
34. Edwards A, Prior L, and the Department of General Practice Working Group, University of Wales College of Medicine. Communication about risk: dilemmas for general practitioners. Br J Gen Pract. 1997;47:739-742.
35. Peshkin BN, DeMarco TA, Brogan BM, Lerman C, Isaacs C. BRCA1/2 testing: complex themes in result interpretation. J Clin Oncol. 2001;19:2555-2565.
36. Hofman KJ, Tambor ES, Chase GA, Geller G, Faden RR, Holtzman NA. Physicians' knowledge of genetics and genetic tests. Acad Med. 1993;68:625-632.
37. Lloyd FJ, Reyna VF, Whalen P. Accuracy and ambiguity in counseling patients about genetic risk. Arch Intern Med. 2001;161:2411-2413.
38. Welch HG, Burke W. Uncertainties in genetic testing for chronic disease. JAMA. 1998;280:1525-1527.
39. Press N, Fishman JR, Koenig BA. Collective fear, individualized risk: the social and cultural context of genetic testing for breast cancer. Nurs Ethics. 2000;7:237-249.
40. Stockdale A. Public understanding of genetics and Alzheimer disease. Genet Test. 1999;3:139-145.
41. Turney J. The public understanding of genetics: where next? Eur J Gen Soc. 1995;1:5-20.
42. Dijck JV. Imagenation: Popular Images of Genetics. New York; New York University Press; 1998.
43. Tambor ES, Bernhardt BA, Rodgers J, Holtzman NA, Geller G. Mapping the human genome: an assessment of media coverage and public reaction. Genet Med. 2002;4:31-36.
44. Nelkin D, Lindee S. The DNA Mystique: The Gene as Cultural Icon. New York, NY: WH Freeman; 1995,
45. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N Engl J Med. 2000;343:141-144.
46. Serving the family from birth to the medical home: a report from the Newborn Screening Task Force convened in Washington DC, May 10-11, 1999. Pediatrics. 2000;106:383-427.
47. American Society of Clinical Oncology, Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol. 1996;14:1730-1736.
48. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet. 1994;55:i-iv.
49. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA. 1994;271:785.
50. Wilfond BS, Nolan K. National policy development for the clinical application of genetic diagnostic technologies. JAMA. 1993;270:2948-2954.
51. Holtzman NA. Are genetic tests adequately regulated? Science. 1999;286:409.
52. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318-2324.
53. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995;57:1457-1462.
54. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996;334:137-142.
55. Condit CM, Ofulue N, Sheedy KM. Determinism and mass-media portrayals of genetics. Am J Hum Genet. 1998;62:979-984.
56. Marteau TM, Lerman C, Genetic risk and behavioural change. BMJ. 2001;322:1056-1059.
57. Senior V, Marteau TM, Peters TJ. Will genetic testing for predisposition for disease result in fatalism? a qualitative study of parents responses to neonatal screening for familial hypercholesterolaemia. Soc Sci Med. 1999;48:1857-1860.
58. Goodman MJ, Goodman LE. The overselling of genetic anxiety. Hastings Cent Rep. 1982;12:20-27.
59. Azuri J, Elstein D, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A. Asymptomatic Gaucher disease implications for large-scale screening. Genet Test. 1998;2:297-299.
60. Menasha JD, Schechter C, Willner J. Genetic testing: a physician's perspective. Mt Sinai J Med. 2000; 67:144-151.
61. Cho MK, Sankar P, Wolpe PR, Godmilow L. Commercialization of BRCA1/2 testing: practitioner awareness and use of a new genetic test. Am J Med Genet. 1999;83:157-163.
62. Geller G, Holtzman NA. A qualitative assessment of primary care physicians' perceptions about the ethical and social implications of offering genetic testing. Qual Health Res. 1995;5:97-116.
63. Hunter A, Wright P, Cappelli M, Kasaboski A, Surh L. Physician knowledge and attitudes towards molecular genetic (DNA) testing of their patients. Clin Genet. 1998;53:447-455.
64. Myriad Genetics Inc. Myriad Genetics and Lab-Corp form exclusive predictive marketing alliance [press release]. December 4, 2001.
65. Cho MK, Arruda M, Holtzman NA. Educational material about genetic tests: does it provide key information for patients and practitioners? Am J Med Genet. 1997;73:314-320.
66. Statement of Steven Gutman, Division of Clinical Laboratory Devices, FDA. Secretary's Advisory Committee on Genetic Testing meeting, Baltimore, Md. May 14-15, 2002.
67. Bureau of Consumer Protection and the Bureau of Economics of the Federal Trade Commission, before the FDA. In the Matter of Direct-to-Consumer Promotion, January 11, 1996. Public Hearing Docket No. 95N-0227. Available at: http://www.ftc.gov/be /v960001.htm. Accessed September 28, 2001.
68. FTC Policy Statement on Deception. Letter from the Commission to Chairman John D. Dingell, Committee on Energy and Commerce, US House of Representatives, October 14, 1983. Available at: http://www,ftc.gov/bcp/policystmt/ad-decept.htm. Accessed October 4, 2001.
69. Prescription Drug Advertising. 64 Federal Register 400 (codified at 21 CFR §202.1).
70. Juengst ET. Caught in the middle again: professional ethical considerations in genetic testing for health risks. Genet Test. 1997/1998;1:189-200.